Amrutajan Health Ltd
NSE: AMRUTANJAN · Pharmaceuticals · sector
₹489.75NSE close 2026-10-26
Key numbers
Market cap₹1,416 cr
Price₹489.75
52w high / low₹760 / ₹476
P/E26.2xSector median 27.9x
P/B3.8xSector median 2.9x
Book value₹128.1
Dividend yield0.93%Sector median 0.48%
ROE15.5%Sector median 11.7%
ROCE19.7%Sector median 12.3%
OPM12.2%Sector median 14.0%
Debt / equity0.00xSector median 0.16x
EV/EBITDA22.0xSector median 18.6x
Interest cover388.8x
Current ratio2.31x
Sales growth 3y+9.8%Sector median +9.6%
Profit growth 3y+13.3%Sector median +13.3%
PEG1.92x
Last 12 months to Jun 2026, Standalone. "Sector median" = middle value of 185 companies in Pharmaceuticals (P/E median leaves out loss-making companies). Tap ? for what a number means.
Things to know
- Cash ₹36 cr vs borrowings ₹0 cr (FY26): cash is higher (net cash).
- Operating profit covered interest 388.8x in the last 12 months.
- No promoter shares are pledged.
- Operating cash flow was below net profit in 4 of the last 5 years (FY26, FY24, FY23, FY22).
- Revenue was higher than a year earlier in 4 of the last 4 quarters.
- Other income was 31% of net profit in the last 12 months.
- Dividend paid in 5 of the last 5 financial years.
- Price ₹489.75 on 2026-10-26: -35.6% from the 52-week high, +2.8% from the 52-week low.
Plain facts from the filings, built by the same fixed rules for every company. A line appears only when the data for it is available. Not a view on the stock.
Charts
Weekly close · high ₹816.05 · low ₹488.35
RevenueNet profit
RevenueNet profit
Quarterly results
| ₹ cr | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 110 | 123 | 135 | 94 | 118 | 141 | 150 | 103 |
| EBITDA | 14 | 23 | 18 | 8 | 17 | 24 | 18 | 4 |
| OPM % | 12.4% | 19.0% | 13.1% | 9.0% | 14.0% | 17.0% | 12.0% | 4.1% |
| Other income | 4 | 4 | 5 | 4 | 4 | 4 | 5 | 4 |
| Net profit | 12 | 19 | 15 | 8 | 14 | 19 | 16 | 4 |
| EPS (₹) | 4.08 | 6.66 | 5.25 | 2.87 | 4.83 | 6.73 | 5.60 | 1.51 |
| Revenue YoY | +7.1% | +14.9% | +10.6% | +9.5% | ||||
| Profit YoY | +18.3% | +1.0% | +6.7% | -47.4% |
Standalone figures where filed. Latest quarter Jun 2026.
Profit & loss (yearly)
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 | TTM |
|---|---|---|---|---|---|---|
| Revenue | 406 | 380 | 421 | 452 | 503 | 511 |
| EBITDA | 79 | 44 | 51 | 58 | 67 | 63 |
| Net profit | 67 | 40 | 45 | 51 | 58 | 54 |
| EPS (₹) | 23.05 | 13.65 | 15.56 | 17.58 | 20.03 | 18.67 |
| Revenue growth | -6.5% | +11.0% | +7.3% | +11.2% | +10.7% | |
| Profit growth | -40.7% | +12.9% | +13.0% | +13.9% | -1.0% | |
| Dividend / share (₹) | 4.60 | 4.60 | 4.60 | 4.60 | 4.60 |
| Compounded growth | 3 years | 5 years | Last 12 months |
|---|---|---|---|
| Sales | +9.8% | +8.6% | +10.7% |
| Net profit | +13.3% | -1.1% | -1.0% |
| EPS | +13.6% | -0.9% | – |
| Share price | – | -18.7% (2y) | -30.8% |
Balance sheet
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Shareholders' equity | – | 291 | 288 | 327 | 370 |
| Borrowings | – | 0 | 0 | 0 | 0 |
| Cash & equivalents | – | 75 | 27 | 83 | 36 |
| Total assets | – | 362 | 367 | 421 | 509 |
| Fixed assets | – | 46 | 47 | 48 | 50 |
| Capital work in progress | – | 1 | 2 | 16 | 105 |
| Investments | – | 0 | 0 | 0 | 0 |
| Receivables | – | 33 | 48 | 56 | 61 |
| Inventory | – | 29 | 29 | 27 | 37 |
| Payables | – | 47 | 56 | 69 | 71 |
Year-end figures from the March annual filing.
Cash flow
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Cash from operations | 53 | 19 | 28 | 51 | 36 |
| Cash from investing | -36 | -2 | 19 | -31 | -21 |
| Cash from financing | -18 | -14 | -48 | -13 | -14 |
| Capex | 23 | 9 | 7 | 36 | 55 |
| Free cash flow | 30 | 10 | 21 | 15 | -19 |
Free cash flow = cash from operations − capex.
Ratios by year
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| ROE % | – | 13.7% | 15.6% | 15.6% | 15.6% |
| ROCE % | – | 18.5% | 21.5% | 21.2% | 21.1% |
| Debtor days | – | 32 | 41 | 45 | 44 |
| Inventory days | – | 58 | 50 | 45 | 56 |
| Payable days | – | 95 | 96 | 113 | 106 |
| Cash conversion cycle (days) | – | -5 | -5 | -23 | -6 |
| Working capital days | – | 189 | 196 | 166 | 120 |
Shareholding
| Holder | % (2026-09-30) |
|---|---|
| Promoters | 46.52% |
| FIIs | 3.47% |
| DIIs | 6.90% |
| of which Mutual funds | 3.60% |
| Public (non-institutions) | 43.08% |
| Quarter | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters % | 46.52% | 46.52% | 46.52% | 46.52% | 46.52% | 46.52% | 46.52% | 46.52% |
| Promoter group | % |
|---|---|
| Goodhealth Holdings Private Limited | 20.15% |
| Sambhuprasad Sivalenka | 10.34% |
| Ramaa Prabhakar Arikirevula | 4.74% |
| Sambhu Prasad Sivalenka | 3.60% |
| Ramaa Prabhakar Arikirevula | 3.02% |
| Ramalingam Ganti | 2.53% |
| Amulya Kamakshi Priya Arikirevula | 2.13% |
| Public holders above 1% | % |
|---|---|
| Isif Equity Long-short Fund | 3.47% |
| Aditya Deorah | 2.31% |
| Pari Washington India Master Fund, Ltd | 2.02% |
| Investor Education and Protection Fund (IEPF) | 1.50% |
| Dipak Kanayalal Shah | 1.16% |
46,186 shareholders. Pledged: 0.00% of promoter shares.
Peers in Pharmaceuticals
| Company | Market cap | P/E | P/B | ROE | ROCE | OPM | Sales 3y | Div yield |
|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | ₹4,17,478 cr | 34.5x | 5.0x | 15.5% | 18.7% | 28.6% | +10.0% | 0.94% |
| DIVISLAB | ₹2,39,825 cr | 82.1x | 14.3x | 18.4% | 23.0% | 34.7% | +10.8% | 0.34% |
| TORNTPHARM | ₹1,53,999 cr | 72.7x | 18.4x | 27.3% | 15.1% | 32.3% | +13.3% | 0.84% |
| ZYDUSLIFE | ₹1,15,808 cr | 25.9x | 4.3x | 17.7% | 16.8% | 27.2% | +16.4% | 0.95% |
| LAURUSLABS | ₹1,11,232 cr | 101.6x | 21.0x | 22.4% | 20.8% | 28.0% | +4.1% | 0.08% |
| CIPLA | ₹1,09,464 cr | 32.5x | 3.2x | 10.3% | 13.2% | 17.7% | +7.4% | 1.18% |
| DRREDDY | ₹1,09,460 cr | 33.9x | 2.9x | 9.0% | 10.1% | 15.5% | +11.0% | 0.61% |
| MANKIND | ₹95,486 cr | 46.7x | 5.9x | 13.4% | 13.8% | 25.1% | +17.7% | 0.04% |
| AUROPHARMA | ₹91,489 cr | 24.9x | 2.4x | 10.5% | 12.8% | 20.0% | +10.6% | 0.26% |
| AMRUTANJAN | ₹1,416 cr | 26.2x | 3.8x | 15.5% | 19.7% | 12.2% | +9.8% | 0.93% |
Business segments (FY26)
| Segment | Revenue | Share | EBIT | Margin |
|---|---|---|---|---|
| OTC Products | ₹328 cr | 65.3% | ₹83 cr | 25.4% |
| Women's Hygiene & Personal Care | ₹140 cr | 27.8% | ₹-3 cr | -1.9% |
| Beverages | ₹32 cr | 6.3% | ₹-6 cr | -20.1% |
| Others | ₹3 cr | 0.6% | ₹-0 cr | -10.0% |
Dividends & corporate actions
| Ex-date | Action | Detail |
|---|---|---|
| 2026-09-11 | Dividend | Dividend - Rs 2.90 Per Share |
| 2026-02-06 | Dividend | Interim Dividend - Re 1 Per Share |
| 2025-11-18 | Dividend | Interim Dividend - Re 1 Per Share |
| 2025-09-16 | Dividend | Dividend - Rs 2.60 Per Share |
| 2025-02-18 | Dividend | Interim Dividend - Re 1 Per Share |
| 2024-11-22 | Dividend | Interim Dividend - Re 1 Per Share |
| 2024-09-13 | Dividend | Dividend - Rs 2.60 Per Share |
| 2024-09-13 | Other | Annual General Meeting |
| 2024-02-20 | Dividend | Interim Dividend - Re 1 Per Share |
| 2023-11-23 | Dividend | Interim Dividend - Rs 1 Per Share |
| 2023-09-14 | Dividend | Annual General Meeting/Dividend - Rs 2.60 Per Share |
| 2023-07-13 | Buyback | Buy Back |
| 2023-02-24 | Dividend | Interim Dividend - Re 1 Per Share |
| 2022-11-14 | Dividend | Interim Dividend - Re 1 Per Share |
| 2022-09-14 | Dividend | Annual General Meeting/Dividend - Rs 2.60 Per Share |
| 2022-02-18 | Dividend | Interim Dividend - Re 1 Per Share |
| 2021-11-16 | Dividend | Interim Dividend - Re 1 Per Share |
| 2021-09-15 | Dividend | Annual General Meeting/Dividend - Rs 2.60 Per Share |
| 2021-02-17 | Dividend | Interim Dividend - Rs 0.80 Per Share |
| 2020-11-19 | Dividend | Interim Dividend - Rs 0.80 Per Share |
Documents
- Annual report FY26
- Annual report FY25
- Annual report FY25
- Annual report FY24
- Annual report FY23
- Announcements NSE filings
- BRSR FY26
- Latest results (data file) XBRL
- Announcements BSE filings
Links go to the original files on the exchange website.
About the company
- Manufacturing: Ayurvedic pharmaceutical preparations and fruit based beverages
- Sales, Distribution and Marketing: Ayurvedic pharmaceutical preparations, fruit based beverages and Women Hygiene Products
| Sector | Healthcare |
| Industry | Pharmaceuticals |
| Sub-industry | Pharmaceuticals |
| Symbol | AMRUTANJAN |
| BSE code | 590006 |
| ISIN | INE098F01031 |
| Face value | ₹1.0 |
| Incorporated | 1936-09-09 |
| Website | www.amrutanjan.com |
| Plants (India / abroad) | 3 / 0 |
From the company's filings (BRSR FY26).
Data built 2026-10-23 from NSE company filings (XBRL: Integrated Filing - Financials + financial results), NSE shareholding & pledge data; price = NSE close 2026-10-26.